These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28058780)

  • 1. Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis.
    Abo Youssef N; Schneider MP; Mordasini L; Ineichen BV; Bachmann LM; Chartier-Kastler E; Panicker JN; Kessler TM
    BJU Int; 2017 Apr; 119(4):515-521. PubMed ID: 28058780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).
    Phé V; Schneider MP; Peyronnet B; Abo Youssef N; Mordasini L; Chartier-Kastler E; Bachmann LM; Kessler TM
    Neurourol Urodyn; 2018 Jan; 37(1):67-82. PubMed ID: 28618110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catheterization for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).
    Tornic J; Sartori AM; Gajewski JB; Cox A; Schneider MP; Youssef NA; Mordasini L; Chartier-Kastler E; Bachmann LM; Kessler TM
    Neurourol Urodyn; 2018 Nov; 37(8):2315-2322. PubMed ID: 29917273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).
    Schneider MP; Tornic J; Sýkora R; Abo Youssef N; Mordasini L; Krhut J; Chartier-Kastler E; Davies M; Gajewski J; Schurch B; Bachmann LM; Kessler TM
    Neurourol Urodyn; 2019 Aug; 38(6):1482-1491. PubMed ID: 31099113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review.
    Schneider MP; Gross T; Bachmann LM; Blok BF; Castro-Diaz D; Del Popolo G; Groen J; Hamid R; Karsenty G; Pannek J; Hoen L'; Kessler TM
    Eur Urol; 2015 Nov; 68(5):859-67. PubMed ID: 26194043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcutaneous Electrical Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review.
    Gross T; Schneider MP; Bachmann LM; Blok BF; Groen J; Hoen LA; Castro-Diaz D; Padilla Fernández B; Del Popolo G; Musco S; Hamid R; Ecclestone H; Karsenty G; Phé V; Pannek J; Kessler TM
    Eur Urol; 2016 Jun; 69(6):1102-11. PubMed ID: 26831506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desmopressin for treating nocturia in patients with multiple sclerosis: A systematic review: A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).
    Phé V; Schneider MP; Peyronnet B; Abo Youssef N; Mordasini L; Chartier-Kastler E; Bachmann LM; Kessler TM
    Neurourol Urodyn; 2019 Feb; 38(2):563-571. PubMed ID: 30653737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Torres-Moreno MC; Papaseit E; Torrens M; Farré M
    JAMA Netw Open; 2018 Oct; 1(6):e183485. PubMed ID: 30646241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of urodynamic findings in predicting upper urinary tract damage in neuro-urological patients: A systematic review.
    Musco S; Padilla-Fernández B; Del Popolo G; Bonifazi M; Blok BFM; Groen J; 't Hoen L; Pannek J; Bonzon J; Kessler TM; Schneider MP; Gross T; Karsenty G; Phé V; Hamid R; Ecclestone H; Castro-Diaz D
    Neurourol Urodyn; 2018 Jun; 37(5):1522-1540. PubMed ID: 29392753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up of the neuro-urological patient: a systematic review.
    Averbeck MA; Madersbacher H
    BJU Int; 2015 Apr; 115 Suppl 6():39-46. PubMed ID: 25891319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
    Medina-Polo J; Adot JM; Allué M; Arlandis S; Blasco P; Casanova B; Matías-Guiu J; Madurga B; Meza-Murillo ER; Müller-Arteaga C; Rodríguez-Acevedo B; Vara J; Zubiaur MC; López-Fando L
    Neurourol Urodyn; 2020 Feb; 39(2):762-770. PubMed ID: 31943361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Cheng T; Shuang WB; Jia DD; Zhang M; Tong XN; Yang WD; Jia XM; Li S
    PLoS One; 2016; 11(7):e0159307. PubMed ID: 27463810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
    Brady CM; DasGupta R; Dalton C; Wiseman OJ; Berkley KJ; Fowler CJ
    Mult Scler; 2004 Aug; 10(4):425-33. PubMed ID: 15327041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and comparison of questionnaires in the management of spinal cord injury, multiple sclerosis and the neurogenic bladder.
    Tsang B; Stothers L; Macnab A; Lazare D; Nigro M
    Neurourol Urodyn; 2016 Mar; 35(3):354-64. PubMed ID: 25620137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom management.
    O'Connor P
    Adv Neurol; 2006; 98():227-55. PubMed ID: 16400837
    [No Abstract]   [Full Text] [Related]  

  • 16. Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.
    De Ridder D; Van Der Aa F; Debruyne J; D'hooghe MB; Dubois B; Guillaume D; Heerings M; Ilsbroukx S; Medaer R; Nagels G; Seeldrayers P; Van Landegem W; Willekens B; Zicot AF
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2033-40. PubMed ID: 23880016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis.
    Bosma R; Wynia K; Havlíková E; De Keyser J; Middel B
    Acta Neurol Scand; 2005 Jul; 112(1):1-5. PubMed ID: 15932348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies of urinary disorders in MS. Practice and algorithms.
    Denys P; Phe V; Even A; Chartier-Kastler E
    Ann Phys Rehabil Med; 2014 Jul; 57(5):297-301. PubMed ID: 24958444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurogenic lower urinary tract dysfunction in the early disease phase of paediatric multiple sclerosis.
    Scheepe JR; Wong YY; van Pelt ED; Ketelslegers IA; Catsman-Berrevoets CE; van den Hoek J; Hintzen RQ; Neuteboom RF
    Mult Scler; 2016 Oct; 22(11):1490-1494. PubMed ID: 26589894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The overactive bladder in multiple sclerosis.
    Fingerman JS; Finkelstein LH
    J Am Osteopath Assoc; 2000 Mar; 100(3 Suppl):S9-12. PubMed ID: 10763312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.